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Abstract
Background: Mucopolysaccharidosis type I (MPS I) is an autosomal storage disease resulting from defective activity
of the enzyme a-L-iduronidase (IDUA). This glycosidase is involved in the degradation of heparan sulfate and
dermatan sulfate. MPS I has severe and milder phenotypic subtypes.
Aim of study: This study was carried out on six newly collected MPS I patients recruited from many regions of
Tunisia.
Patients and methods: Mutational analysis of the IDUA gene in unrelated MPS I families was performed by
sequencing the exons and intron-exon junctions of IDUA gene.
Results: Two novel IDUA mutations, p.L530fs (1587_1588 insGC) in exon 11 and p.F177S in exon 5 and two
previously reported mutations p.P533R and p.Y581X were detected. The patient in family 1 who has the Hurler
phenotype was homozygous for the previously described nonsense mutation p.Y581X.
The patient in family 2 who also has the Hurler phenotype was homozygous for the novel missense mutation p.
F177S. The three patients in families 3, 5 and 6 were homozygous for the p.P533R mutation. The patient in family 4
was homozygous for the novel small insertion 1587_1588 insGC. In addition, eighteen known and one unknown
IDUA polymorphisms were identified.
Conclusion: The identification of these mutations should facilitate prenatal diagnosis and counseling for MPS I in
Tunisia.Background
Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disorder caused by the deficient
activity of the enzyme of a-L-iduronidase (IDUA, EC 3.2.1.76). This glycosidase is involved in the degradation of
heparan sulfate and dermatan sulfate. The clinical phenotype of MPS I ranges from the very severe in Hurler
syndrome (MPS IH) to the relatively benign in Scheie syndrome (MPS IS), with an intermediate phenotype
designated Hurler/Scheie (MPS IH/S) [1]. Isolation of complementary and genomic DNAs encoding human a -L-
iduronidase [2,3] have enable the identification of mutations underlying the enzyme defect and resulting in MPS I
clinical phenotype. More than 100 mutations have been reported in patients with the MPS I subtypes (Human
Gene Mutation Database; http://www.hgmd.org). High prevalence of the common mutations p.W402X and p.Q70X
has been described; both of them in the severe clinical forms [4,5]. A high prevalence of common mutation p.
P533R has also been described in MPS I patients with various phenotypes [5,6]. In addition, rare mutations
including single base substitution, deletion, insertion and splicing site mutation have been identified [7], indicating
a high degree of allelic heterogeneity in IDUA gene.
Here, we described two novel IDUA mutations in MPS I Tunisian patients. These lesions were homoallelic in all the
patients of the six families investigated as consanguineous marriages are still frequent in Tunisia [8].
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Patients
Six Tunisian unrelated families with MPS I were investi-
gated. The MPS I patients were diagnosed in paediatric
clinics of hospital of northern and southern Tunisia
(Figure 1). The patients were all offspring of consangui-
neous marriages between first, second or third cousins.
This study was approved by the Ethics committees of
the Tunisian hospitals, and all families gave informed
consent. Blood samples were collected from the six
patients, their parents, and unaffected siblings and rela-
tives. The clinical diagnoses were confirmed by enzy-
matic assays (Table 1).
IDUA activity
IDUA activity was determined in sonicated leukocyte
pellets as described using the artificial substrate 4-
methylumbellifery-a-L-iduronide [9].
IDUA mutation analysis
G e n o m i cD N Aw a si s o l a t e df r o mv e n o u sb l o o db yt h e
phenol/chloroform procedure. Each of the 14 exons and
flanking intron-exon junctions of the IDUA gene were
amplified from genomic DNAs from the patients and
their parents as described previously [10].
Polymerase chain reaction (PCR) was carried out in a
volume of 50 μl containing 100 ng genomic DNA, 0.2
mmol/L dNTPs, 0.4 μM of each primer, 1.5 mmol/L
Mgcl2, 10% (v/v) DMSO, and 0.15 μl (0.75 units) of Taq
Qbiogen (Promega).
Results
The affected probands in the six families had the typi-
cal Hurler phenotype. Two novel mutations, p.L530fs
(1587_1588 inGC) in exon 11, and p.F177S in exon 5,
and two previously reported mutations, p.P533R and p.
Y581X, were detected in the affected patients and their
respective parents from the six MPS I families (Table
2). The proband of family 1 with the Hurler phenotype
was homozygous for the previously reported p.Y581X
nonsense mutation (Figure 2a). The affected MPS IH
patient in family 2 was homozygous for the novel p.
F177S missense mutation. This mutation was due to a
thymine -to- cytosine transversion in codon 177,
resulting in the substitution of a polar phenylalanine
to an uncharged polar serine residue (Figure 2b). The
three affected siblings in families 3, 5 and 6 were
homozygous for the previously reported p.P533R mis-
s e n s em u t a t i o n( F i g u r e2 c ) .T h ep r o b a n do ff a m i l y4
was homozygous for a novel small insertion mutation
1587_1588 inGC (Figure 2d). This novel framshift
(Leu530fs) in exon 11 changed codon 530 for leucine
(CTG) to a premature termination codon (TGA), 30
amino acids downstream from the termination codon
of the enzyme glycopeptide. In addition to these muta-
tions, eighteen previously identified and one novel
polymorphisms were identified in the Tunisian MPS I
alleles (Table 2) [2,7,11,12].
The previously reported polymorphisms were detected
in families 4 and 6, including: p.A8A (c.24 A > C), p.
A20A (c.60G > A); p.H33Q (c.99 T > G), p.Q433Q
(c.99T > G), IVS2-44 (c.300-44C > T); p.R105Q (c.314G
> A); p.N181N (c.543 T > C), IVS5-45 (c.590-45G > C);
IVS5-8 (c.590-8C > T); p.A314A (c.942G > C); IVS7+48
(c.972+48A > G), IVS7-45 (c.973-45 G > C; p.A361
(c.1081G > A; p.T388T (c.116 G > C); p.V454I (c.1360G
> A); IVS9+36 (c.1402+36T > C), p.R489R (c.1467C >
T), IVS12+72 (c.1727T > G), and one previously unre-
ported polymorphism, 3’UTR+44 (c.1962+44G > C).
Discussion
MPS I is the most common mucopolysaccharidosis
worldwide, with an average incidence of about 1.7 in
100.000 live births for the severe and mild forms [13].
The incidence of MPS I in Tunisia is also high, esti-
mated at 0.63 in 100.000 live births [14], owing to the
high rate of consanguinity [15].
Figure 1 Regional distribution of studied MPS I patients in
Tunisia.
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been described in patients with the MPS I subtypes
(Human Gen Database, http://www.hgmd.org).
The molecular analysis of the six newly collected
patients in Tunisian families allowed the identification
of four mutations including a small insertion
(1587_1588 inGC), a novel missense mutation (p.F177S)
and two previously reported mutations, p.P533R and p.
Y581X (Table 2). Of note, the common Caucasian
IDUA mutations, p.Q70X and p.W402X, were not pre-
sent [7].
Patient 1 from family 1 was homozygous for the pre-
viously reported p.Y581X mutation in exon 13 of the
IDUA gene. The p.Y518X mutation was first described
in one patient of Croatian origin. This patient was het-
eroallelic for the p.Y581X mutation and the Ile583delC
mutation [16].
A patient 2 from family 2 was homozygous for the
novel p.F177S mutation. This mutation causes a sever
instability or loss of IDUA protein function, since the
177 residue was predicted to form the strands of the b
barrel with the catalytic residues perched on the C
terminal ends of the b strands [17]. The predicted
IDUA active site showed different residues, among
which the residue Glu178 which is near the Phe177.
This mutation presumably resulted from slipped mis-
pairing and repairing during replication. Our study iden-
tified the p.177S mutation in patient which had the
severe phenotype and undetectable IDUA activity. This
concept is consistent with the fact that the phenylala-
nine at IDUA residue 177 is highly conserved in
evolution.
A patient four from family four was homozygous for
the novel 1587_1588 inGC mutation that leads to the
lack of 30 aminoacid at the amino terminus of the
IDUA protein (p.Leu530fs).
The insertion (GC) occurred between two direct
repeats (GC) that were separated by only three bases
(CCC). The patient 4 did not have detectable IDUA
activity and presented with the severe Hurler phenotype.
Table 1 Laboratory and clinical findings of the six MPS I patients
Families Consanguinity Tunisian
origin
Sex Age of
diagnosis
Age Leukocyte
IDUA
activity (%
normal)
Mutations
identified
Polymorphisms sequences variants
Family 1
Patient 1
3
rd cousins Makthar F 2 years
5 days
9 years 0.1% p.Y581X No polymorphisms
Family 2
Patient 2
2
nd cousins Tunis F 1 year
6 months
11 years
(died)
0.1% p.F177S No polymorphisms
Family 3
Patient 3
3
rd cousins Sfax M 2 years 12 years 0.2% p.P533R No polymorphisms
Family 4
Patient 4
1
st cousins Bizerte M 1 year
8 months
3 years
(died)
< 0.1% p.L530fs
(1587_1588inGC)
p.H33Q (c.99 T > G), p.R105Q (c.314G > A), p.
N181N (c.543 T > C), IVS5-45 (c.590-45) G > C),
IVS5-8 (c.590-8C > T), p.A314A (c.942G > C), IVS7
+48(c.972+48A > G), IVS745(c.973- 45G > C),
p.A361T (c.1081G > A), p.T388T (c.1164G > C),
p.V454I (c.1360G > A), IVS9+36 (c.1402+36T > C),
p.R489R (c.1467C > T), IVS12+72 (c.1727T > G)
Family 5
Patient 5
3
rd cousins Djerba
Island
M 1 year
4 months
4 years 0.2% p.P533R No polymorphisms
Family 6
Patient 6
2
nd cousins Djerba
Island
M 1 year 2 years 0.3% p.P533R p.A8A (c.24 A > C, p.A20A (c.60G > A); p.Q433Q
(c.99T > G), IVS2-44 (c.300 44C > T); p.R105Q
(c.314G > A); p.N181N (c.543 T > C), IVS5-45
(c.590-45G > C); IVS5-8 (c.590- 8C > T); p.A314A
(c.942G > C); IVS7+48 (c.972+48A > G), IVS7-45
(c.973-45 G > C; p.A361 (Tc.1081G > A); p.T388T
(c.116G > C); p.V454I (c.1360G > A); IVS9+36
(c.1402+36T > C), p.R489R (c.1467C > T), IVS12
+72 (c.1727T > G), 3’UTR+44 (c.1962+44G > C).
Table 2 MPS I mutations in Tunisian patients
Mutations Nucleiotide change Base (cDNA)
a Exon Codon Predicted protein change
p.F177S
p.L530fs
p.P533R
p.Y581X
T>C
1587_1588insGC
C>G
C>G
530
1587
1598
1743
5
11
11
13
177
530
533
581
Phenylalanine to serine
Frame- shift, premature stop
Proline to Arginine
Tyrosine to stop
a c DNA sequence from NCBI (IDUA NM-000203) with+1 being the A of the ATG initiation codon (n88).
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tively were homozygous for the p.P533R mutation.
These patients had undectable IDUA activity and the
typical Hurler phenotype. The p.P533R missense muta-
tion in exon 11 resulted in a non conservative substitu-
tion of a neutral proline for a basic arginine.
The IDUA model begins at residue 36 of the linear
sequence and terminates at residue 522, as this is the
longest section that can be reliably predicted on the
basis of the crystal structure of of the b-D-xylosidase
from Thermoanaerobacterium saccharolyticum (XyTS,
EC 3.2.1.37) [18]. As a result, residues 523-653 do not
appear in the IDUA model, consistent with the finding
that a proline residue in codon 533 is incapable of form-
ing the main chain hydrogen bonds. A non conservative
substitution of a neutral proline for a basic arginie could
be predicted to drastically change the orientation of the
secondary structure in IDUA protein leading to a severe
disease phenotype.
The basis of such regional distribution of p.P533R
mutation is not clear. This mutation has been identified
in 92% of mutant alleles in 13 MPS I patients from
Marroco [6], in 11% of mutant alleles of 27 MPS I
patients from Sicily [19], in 62.5% of mutant alleles in
10 MPS I patients from Tunisia [20] and not identified
in 3 MPS I patients from Egypt [21], suggesting that the
p.P5323R allele possibly originated from a common
founder from the Islamic occupation of Sicily [22].
A large number of polymorphisms and non patho-
genic sequence variants have been described in the
IDUA gene [7,23,24] (Table 2). The effect of these
sequences variants on the IDUA activity has not been
clearly defined especially when they are associated with
specific mutations causing the Hurler/Scheie and Scheie
phenotypes [7]. The effect of the noncoding [IVS2-44
(c.300-44C > T);IVS5-45 (c.590-45G > C); IVS5-8
(c.590-8C > T);IVS7+48 (c.972+48A > G), IVS7-45
(c.973-45 G > C; IVS9+36 (c.1402+36T > C), IVS12+72
(c.1727T > G),3’UTR+44 (c.1962+44G > C)] and coding
[p.A8A (c.24 A > C), p.A20A (c.60G > A); p.H33Q (c.99
T > G), p.Q433Q (c.99T > G), p.R105Q (c.314G > A); p.
N181N (c.543 T > C); p.A314A (c.942G > C); p.A361
     
       
a  b 
c  d 
W+ 
W 
W+ 
W 
Figure 2 Direct sequencing of IDUA gene in Tunisian MPS I patients. 2a: Patient 1 (family 1): p.Y581X point mutation. 2b: Patient 2 (family
2): p.F177S point mutation. 2c: Patients 3, 5 and 6 (families 3, 5 and 6): p.P533R point mutation. 2d: Patient 4 (family 4): p.L530fs frame shift
mutation. (w): mutant sequence, (w+): wild -type sequence.
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Page 4 of 6(Tc.1081G > A; p.T388T (c.116 G > C); p.V454I
(c.1360G > A); p.R489R (c.1467C > T)] polymorphisms/
sequence variants on IDUA expression in the Hurler
patients from the Tunisian families is unknown [25].
Our study showed a heterogeneous pattern of muta-
tions and polymorphisms among MPS I Tunisian
patients.
The results of recent studies support the evidence of
mutational heterogeneity of the IDUA, IDS and GALNS
genes in patients with MPS I [25], MPS II [26] and MPS
IVA [27] respectively. These MPS patients have different
clinical presentation ranging from severe to mild. Since
most patients have unique mutations, a comprehensive
genotype-phenotype correlation is not feasible. At any
rate, even in presence of recurrent mutations, a correla-
tion has proved inapplicable. For example, the missense
p.P533R mutation was usually reported associated with
a severe phenotype [5], whereas this lesion identified on
the contrary in our patients was found associated with
mild and severe forms of the disease. This type of obser-
vation implicates others modifying or non genetic factor
in the clinical presentation of disease.
A more comprehensive analysis of MPS I patients is
essential. This must comprise not only a molecular
screening for other known mutations, but also a com-
plete screening for new mutations. In addition, a com-
prehensive clinical and epidemiological investigation
could help assign the ethnic background of these
patients.
Conclusion
In summary, two novel mutations were identified in six
MPS I patients from six Tunisian families. The severe
missense mutation p.F177S was detected in one family
and presumably resulted in misfolding and degradation
of the mutant glycopepide. The other lesion was a
severe small insertion 1587_1588 insGC that predicts
premature termination of the IDUA protein. The identi-
fication of these mutations could provide genotype/phe-
notype correlations for the severe MPS I subtypes,
accurate carrier detection, and prenatal diagnosis for
MPS I families.
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